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The lack of biomarkers for an early diagnosis of neurodegenerative disorders (NDs) has hampered the 
development of therapeutics whose effect would be enhanced by a timely intervention. Neurofilaments 
light chain (Nf-L), an integral part of the axonal structure, has emerged as a robust fluid biomarker 
for fatal neurodegenerative disorders like amyotrophic lateral sclerosis (ALS). To facilitate large-scale 
studies into early-stage neurodegeneration, reduce costs of samples collection/processing and cold-
chain storage, we describe the measurement of Nf-L in blood fractions obtained from dry blood spots 
(DBS) and dry plasma spots (DPS), two filter paper-based remote blood collection tools. To test the 
feasibility of using this approach, Nf-L analysis in DBS/DPS is compared to that in plasma obtained 
from the same blood sample, looking at Nf-L discriminatory power in the clinical stratification of ALS 
compared to healthy controls. With the best pre-analytical treatment for total protein recovery and 
using highly sensitive immunoassays, we report the detection of different Nf-L levels in DBS elute 
compared to reference plasma and DPS from the same blood samples. However, Nf-L measurement 
in DBS elutes provides a very good discrimination of ALS from healthy controls which is comparable to 
that obtained using plasma Nf-L assays. With the available immunodetection methods, we show that 
Nf-L measurement based on DPS microsampling is similar to that in plasma. The filter-paper biophysical 
characteristics and the interference of high haemoglobin concentration released by erythrocyte lysis 
is likely to perturb Nf-L detection in DBS elute. Further studies into DBS-based Nf-L detection and its 
analytical optimization are needed to make this method suitable for routine Nf-L blood analyses in 
neurodegeneration.
The rise of neurodegenerative disorders (NDs) in the ageing population is increasing demand on already stretched 
Health Services and is a major financial burden for the society1. The development of tools for early diagnosis 
allowing timely therapeutic interventions is one of the responses to this problem2. To this end, it is important to 
acquire easily measurable, cost-effective and sensitive biomarkers of axonal loss, the process underpinning neu-
rodegeneration, which can also be used as surrogate markers of treatment response in clinical trials. The design 
and the implementation of effective clinical trials can also be improved by better means of biomarkers-based 
clinical stratification. Biological predictors of rate of disease progression, for example, will reduce uncertainties 
surrounding the true disease modifying effect of a medication in clinically heterogeneous diseases.
The measurement in blood and cerebro-spinal fluid (CSF) of neurofilaments (Nf), the building blocks of 
neurons and axons, is increasingly seen as a breakthrough in the development of a universal biomarker of neu-
rodegeneration and potentially useful also to study ageing and environmental exposure like trauma3,4. CSF, the 
main repository of by-products of neuronal destruction, is enriched in Nf and unlike other peptides linked to 
neurodegeneration such as Tau and Amyloid beta, Nf expression in CSF is highly correlated to that in blood5,6. 
As serial lumbar punctures to procure CSF for biomarkers analysis may be impractical in advanced and uncoop-
erative patients and disease monitoring by structural and functional brain imaging is expensive and logistically 
complex7, blood may represent the ideal source to track any meaningful disease signal of neurodegeneration 
cost-effectively in large biomarkers studies and clinical trials. Both light and heavy neurofilament chain (Nf-L; 
Nf-H) measurement in blood is now possible thanks to highly sensitive immunodetection platforms like Meso 
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Scale Discovery (MSD) and single molecular array (Simoa), which provide readings at picogram and femptogram 
levels respectively3,8–10. Therefore, the role of Nf as biomarkers of neurodegeneration can only be fully appreciated 
through a large-scale survey of their expression at a population level, factoring variables including age, ethnic 
origin as well as the association of relevant co-morbidities.
To enable large-scale biomarker studies, the costs of sensitive analytical platforms and of properly funded and 
staffed services are considerable. Budgets include patients attendance to busy outpatient departments, phlebot-
omy, sample processing and storage at high energy-consuming super-low temperatures11. High-costs and low 
energy efficiency have pushed alternative means of samples collection and storage ensuring a similar analytical 
performance as traditional forms of sampling, but with no or less requirements for sample processing. Dried 
plasma spot (DPS) and dried blood spot (DBS) on filter paper can be a remote, quick and inexpensive way of 
obtaining blood microsamples for the measurement of a large number of analytes and their use may be a feasible, 
non-expensive and energy-saving means of disease screening and treatment monitoring in non-hospitalized, 
public health settings12,13. The use of DBS and DPS has no requirements in terms of cold chain for transport and 
storage. Plasma and serum obtained from processed blood can be directly spotted on to absorbent paper, stored 
at room temperature, and later reconstituted with a simple elution step. Recently, a new concept of plasma 
prep cards (Noviplex™) has become available. This next generation DBS system makes it possible, after spot-
ting blood drops onto a card, to physically remove blood cells which are compartmentalized in the superficial 
layer of the card. The result is a stable DPS which delivers up to 7.5 µl plasma, which can be used to generate 
analytical results that better agree with plasma analysis by conventional methods (https://www.novilytic.com/
noviplex-plasma-prep-cards/). Protocols for the use of DBS and DPS to measure a range of analytes for diagnostic 
purposes like human immunodeficiency virus, Cytomegalovirus, Mycobacterium Tuberculosis, Leishmania and 
to test the detection efficiency of low abundance analytes like cytokines are now available10–17. Analytical perfor-
mance for a number of target molecules in DBS and matched plasma/serum samples may differ as a measure of 
how the filter matrix modifies the relative composition of the blood components in the final product of elution.
Here we have used highly sensitive immunodetection assays9,14–16 to test neurofilament light chain (Nf-L) 
expression in elute from Protein Saver 903 cards DBS and from DPS stored at ambient temperature and com-
pared these to standard Nf-L plasma measurement. Taking advantage of red cells, plasma and DBS extracted 
from the same blood samples from healthy controls and patients with amyotrophic lateral sclerosis (ALS), a 
clinically heterogeneous and invariably fatal neurodegenerative disorder, we have looked at whether DBS-based 
Nf-L measurements maintain the same discriminatory power reported using plasma assays where Nf-L differ-
entiates healthy from affected individuals as well as fast versus slow progressing ALS patients. We show that DBS 
Nf-L reading is different from that obtained in matched plasma, although DBS Nf-L detection enables a good 
separation of ALS from healthy controls (HC), similarly to matched plasma Nf-L levels. The differences in Nf-L 
detection is likely to be due to haemoglobin interfering with Nf-L detection in the haemolytic elute from the saver 
card. Elute from DBS presents a different proteolytic profile for Nf-L when compared to matched plasma which 
may explain the different patterns of immunodetection. Finally, differences between Nf-L detection in DBS elute 
and matched plasma are due to the high dilution of DBS products of elution compared to the highly concentrated 
proteinaceous mix in plasma, after removal of the blood corpuscular fraction. The study provides the basis to 
further explore the remote collection of blood micro-samples immobilized on dry filter paper for an efficient and 
cost-effective use of Nf analysis in large-scale biomarkers studies.
Results
Patients and samples selection. 17 Healthy Controls (HC) with no medical history of disorders known 
to affect Nf levels like mechanical injuries, ischaemic or inflammatory pathologies of the central nervous system 
or peripheral neuropathies (male/female ratio: 6/11; average age at sampling: 58 (±7)) along with 5 neurological 
controls (NC, male/female ratio: 3/2; average age at sampling: 70 (±11)) including congenital peripheral neurop-
athy, myasthenia gravis, frontotemporal dementia, progressive muscle atrophy and parkinsonism) and 20 age/
gender-matched individuals with a diagnosis of amyotrophic lateral sclerosis (El Escorial diagnostic criteria17) 
were included in the study. ALS patients were sub-grouped in fast (ALS-Fast, average age at sampling: 61(±13)) 
and slow (ALS-Slow, average age at sampling: 70 (±10)) progressing individuals based on progression rate to 
last visit (PRL: ALS-Slow < 0.6 and ALS-Fast > 0.9). Demographic and clinical characteristics are reported in 
Table 1. 30 ml blood was drawn by venepuncture from each participant to obtain plasma and serum and between 
0.7 to 1 ml was spotted on to 2 protein saver cards (PSC), one stored at room temperature and one at −80 °C. To 
obtain dry plasma spots (DPS), we either spotted blood drops on to a Noviplex cards (a multi-layered card system 
supporting a simple two-step recovery of plasma spots; https://www.biocompare.com/23540-Blood-and-Tissue-
Products/5017746-Noviplex-Cards-Dried-Plasma-Spot-Technology/) or spotted processed plasma (and serum) 
directly onto a PSC.
Elution conditions and total protein concentration on elution. Total proteins concentration was 
tested using Pierce (Pierce™ BCA Protein Assay Kit - cat. 23225) and Bradford methods (Bio-Rad Protein Assay 
Kit II Bio-Rad - cat. 5000002) to evaluate elution conditions for DBS stored at room temperature (RT) or at 
−80 °C, using matched plasma samples as reference (Fig. 1). A subset of DBS kept at -80 were air dried (a.d.) for 
10 minutes before elution. Volume, pH and presence of a protease inhibitor were the eluent conditions tested and 
DBS were kept at room temperature (RT) for one hour or overnight (ON) at 4 °C on elution. In DBS from a group 
of 22 controls, storage conditions (RT vs −80 °C) after blood collection (with or without a.d. before elution) did 
not affect protein concentration (Fig. 1A). However, ON elution at 4 °C resulted in a significant reduction of total 
protein content compared to 1-hour elution at 37 °C (Fig. 1A). The buffer pH (range of 4.5–7.4) changed the 
total protein content in the elutes and a.d. treatment of −80 °C stored cards showed a higher and more consistent 
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protein concentration (Fig. 1B). The presence of Tween20 in the eluent did not modify the yield of total proteins 
in the products of elution (Fig. 1C).
With increasing volumes of elution buffer, there was linearity of total protein concentration in the final elute 
with up to a 1/100 dilution factor. Linearity was lost for higher elution factors (Fig. 1D). Total protein content 
measured 24-hour after elution did not differ significantly if proteases inhibitor (PI) was added to the elution 
buffer or not (Supplementary Fig. 1). There were no differences in total protein levels in DBS elutes and in 
matched plasma samples comparing participant sub-groups including ALS (ALS-Fast n: 11; ALS-Slow n: 9) and 
Healthy Controls (HC n: 14), suggesting that the biological differences between ALS sufferers and healthy indi-
viduals did not impact in the overall protein concentration in the elutes from DBS. Average total protein concen-
tration was 7 to 8 folds higher in plasma samples compared to matched DBS elutes (Fig. 1E). Furthermore, total 
protein levels of the elutes from DBS of the three subgroups appeared in a much tighter range (smaller standard 
deviations) compared to the variability and wider range of concentrations observed in total protein levels detected 
in the matched plasma samples (Fig. 1E). No significant correlation between DBS and matched plasma samples 
total protein levels was found (Supplementary Fig. 2). As previously reported in the literature18, protein recovery 
from DBS did not change using different detergents (Fig. 1B,D).
These findings indicate that the physical properties of the protein saver card (PSC) dry paper may condition 
both absorption of blood and release of proteins, a process which may be independent from the amount of total 
proteins which maintains a linear relation to the volume of eluent (lost above 100 µl dilution, Fig. 1D).
Total protein levels in DBS elutes positively correlated with the source blood samples haematocrit (p = 0.0019) 
and haemoglobin (p = 0.0055) levels (Fig. 1F), while no correlation was found between plasma total proteins and 
haematocrit/haemoglobin (Supplementary Fig. 3). This may be explained by the so-called chromatographic effect 
previously described by Denniff, P et al.19, which defines how the retention of whole blood is affected by haema-
tocrit and by the physical characteristics of PSC. The reported linear and inverse correlation between spot area 
and blood haematocrit at a given volume of blood (the higher the haematocrit value the smaller the blood spot 
and vice versa) may influence the relative concentration of haemoglobin and also of total proteins eluted from the 
fixed (punched) area of the DBS, which in our case is 6 mm in diameter (Fig. 1F). Haematocrit is also known to 
introduce a bias in the detection of most analytes in DBS elutes20,21.
Based on the above results, to test total proteins and Nf-L in elution products, we have utilised DBS stored at 
RT treated with 60 µl of elution buffer for 1-hour at 37 °C.
Qualitative analysis of products of elution from dry spots and reference plasma samples by gel 
separation. SDS Page gel electrophoresis and Western blot analysis were performed to resolve plasma and 
serum fractions and compare them to the elutes from DBS, DPS and from filter paper spotted with serum (dry 
serum spot; DSS; Fig. 2) obtained from the same blood samples. 100 micrograms of total protein obtained from 
DBS/DPS/DSS elutes and from plasma/serum samples were loaded in a Nu-Page 4–12% Bis-Tris gradient gel. 
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Table 1. Summary of clinical/demographic information and of the biochemical markers tested in the study 
participants. The level of neurological impairment is represented by the ALS functional rating scale-revised 
(ALSFRSr), comprising a scale of 1 to 48, with lower scores corresponding to a higher degree of neurological 
impairment. ALS patients are grouped based on the rate of disease progression including fast-progressing (ALS-
Fast) and slow-progressing (ALS-Slow). Progression rate at last visit (PRL) is calculated as 48 (approximation 
at disease onset) minus the ALSFRSr score at last visit divided per the number of months from disease onset 
to last visit. For the purpose of this study, ALS-Fast is considered as PRL > 0.9 and ALS-Slow PRL < 0.6. Nf-L 
levels were measured using the mesoscale discovery system (MDS) and single molecular array (Simoa). *Equal 
loading protein concentration (10 µg/µl). **Additional ALS patients whose matched plasma and Np-DBS have 
been tested by Simoa for Nf-L. ***Linear correlation analysis of Nf-L levels between matched plasma and 
DBS elutes, tested using MSD (1), Simoa (2) and linear correlation analysis of Nf-L levels between matched 
plasma and Np-DPS elutes tested on Simoa (3). HC: Healthy Control. Neur-Ctr: Neurological controls. ALS: 
amyotrophic lateral sclerosis.
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Figure 1. Analysis of DBS elution conditions. (A) Total protein concentration in elutes obtained from DBS 
stored at room temperature, at −80 °C and at −80 °C and air dried (a. d.) for 10 minutes before elution. 
Elution is performed with buffer for 1 hour at 37 °C or overnight (ON) at 4 °C. There is no variation of total 
protein concentration in elutes obtained from DBS kept at different storage conditions but there is a significant 
reduction of total protein concentration when the elution is undertaken ON at 4 °C (Bradford measurement, 
multiple comparisons Kruskal-Wallis test; RT p = 0.03, −80 °C a.d. p = 0.0006, −80 °C p = 0.002); (B) total 
protein content in elutes according to pH, storage conditions and use of Tween20 or Barb2. Elution with 
PBS + Tween20 at 7.4 pH of air-dried DBS stored at −80 °C has the best yield and less variability of total protein 
concentration in elution products (Bradford measurement; multiple comparisons Kruskal-Wallis test, Tween20 
RT vs −80 °C p = 0.007, Tween20 vs Barb2 p = 0.008); (C) no changes in total protein concentration (Mann-
Whitney test, p = 0.33) when elution is performed with or without Tween in the buffer (Pierce measurement). 
(D) Increasing volumes of elution buffer show linearity in total protein concentration in the elutes up to 1/100; 
linearity is lost for higher elution volumes; (E) total protein concentration (Pierce measurement) in DBS 
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Visual inspection of the gels revealed equivalent band profiles when plasma was compared to DPS and serum to 
DSS (Fig. 2), suggesting that the elution from filter paper spotted with serum and plasma generated fluids that 
are indistinguishable from plasma and serum obtained using standard blood processing. Densitometric analysis 
confirmed similar concentrations for plasma, serum and related DPS/DSS (data not shown). DBS elutes electro-
phoresis revealed similar but fainter bands when compared to plasma and serum (and related DPS, DSS), while 
additional large bands were visible at lower molecular weight likely to represent products of haemolysis (Fig. 2). 
Banding intensity did not change with the chemical conditions of elution, including pH and presence of Tween 
20 (data not shown).
Neurofilaments analysis by Meso Scale Discovery (MDS) and single molecular array 
(Simoa). Nf-L analysis was performed in blood samples from 20 Slow/fast ALS and 22 controls (including 17 
healthy and 5 neurological controls) using MSD and Simoa platforms, the two most sensitive immunodetection 
platform for Nf-L analysis currently available9. The choice of these cohorts was based on previously published 
data demonstrating that plasma Nf-L provides a robust means of stratification of ALS between fast and slow 
progressing individuals and separation between ALS and controls, including healthy individuals and those with 
other neurological conditions3,6. Our goal was to ascertain whether Nf-L analysis in blood products obtained 
from non-conventional DBS or DPS storage methods reproduced the same readings obtained from plasma and 
had the same discrimination power when comparing ALS to controls, or stratifying ALS according to rate of dis-
ease progression. Individuals with a neurological disease other than ALS were added to the control mix in order 
to include samples expected to have higher levels of Nf-L and test sensitivity and specificity for ALS diagnosis in 
plasma and DBS-derived samples.
Given the reported filter paper and haemoglobin effects in determining the protein concentration in the final 
products of DBS elution19, Nf-L immunodetection was performed using equivalent loading volumes normalised 
to each sample haematocrit (Hct) levels (1st experiment: MSD platform) and equivalent protein concentrations 
(2nd experiment: Simoa platform) as reported below.
Nf-L measurement in plasma samples by MSD using the same starting volume showed the previously 
described up-regulation of Nf-L in ALS-Fast compared to ALS-Slow and HC in plasma6 (Fig. 3A.1), while in 
matched DBS elutes, there was a trend for higher expression in ALS-Fast compared to ALS-Slow and HC of 
the Nf-L/haematocrit ratio which did not reach statistical significance (Fig. 3A.2). A mild correlation between 
Nf-L levels in DBS elutes and matched plasma samples expression was identified when using the Passing–Bablok 
regression statistical analysis, where the Nf-L/haematocrit ratios were plotted on the x axis (Fig. 3A.3).
Next, to circumvent the bias of DBS elution and chromatographic effect due to haematocrit and DBS phys-
ical properties on total protein concentration, we have tested Nf-L in the same samples using a more sensitive 
platform like single molecular array (Simoa – Quanterix)9 and the same amount of total protein was loaded for 
DBS elutes and for plasma samples. Equal loading concentration and the use of Simoa resulted in a good separa-
tion of ALS-Fast from ALS-Slow and HC using DBS elutes, along with what seen with matched plasma samples 
(Fig. 3B.1,B.2). As previous studies on Nf-L fluid expression have identified a strong association with age (22) 
and considering the average age difference of our controls and ALS patient subsets (Table 1), the Nf-L group 
analyses (Fig. 3A1,B1) were also performed after age adjustment. There were no differences in the reported group 
separation after age adjustment (data not shown). Receiver operating characteristic (ROC) analysis was used to 
compare the performance of plasma Nf-L and matched DBS elutes Nf-L to disciminate ALS individuals from con-
trols (plasma: p < 0.0001, AUC: 0,9433; DBS elute: p < 0.0001, AUC: 1; Fig. 3C.2). Separation of ALS from con-
trols was achieved with high level of specificity and sensitivity using Nf-L levels from both plasma and matched 
DBS. Linear regression analysis of Nf-L expression values in plasma and DBS elutes showed a good correlation 
(Fig. 3B.3; p < 0.0001- R2 = 0.7). Normalization with haemoglobin or haematocrit of the Nf-L concentration in 
DBS elute did not improve the statistical significance and the separation in the group and ROC analyses (data not 
shown). In line with what observed in our total protein analysis in DBS elute, Nf-L expression levels were on aver-
age 2.5-fold lowers in DBS elutes compared to that in matched plasma samples, with a much tighter distribution 
around the mean compared to the variability seen in plasma Nf-L levels (Fig. 3B.1,B.2).
Nf-L levels measured in elutes from 13 DPS obtained using Noviplex cards microsampling (Np-DPS), inclu-
sive of healthy controls as well neurological controls and ALS patients, showed a high correlation with Nf-L levels 
measured in the same volume of matched plasma samples (p < 0.0001; R2 0.9) (Fig. 3C.1). Both Np-DPS elutes 
and matched plasma samples were at the same dilution fold before analysis (Fig. 3C.1).
Western blot analysis of Nf light chain (Nf-L) in plasma, DBS elute and red blood cells. Western 
blot (WB) analysis with anti-Nf-L Ab identified Nf-L bands at different molecular weight in plasma and DBS 
elutes, in keeping with different Nf-L proteolytic profiles (Fig. 4A). In HC and ALS patients plasma, WB detected 
a 22 kDa Nf-L band with a significantly higher expression in ALS (Fig. 4C). In DBS elutes, Nf-L bands were 
detected at 52 (stronger intensity), 49, 28 and 22 kDa (lighter intensity; Fig. 4A). The 52 kDa bands in DBS did 
not significantly differentiate ALS patients from controls (Fig. 4D). To gather more information on the source 
of Nf-L in the DBS elute, we have repeated the same experiment comparing plasma to red blood cells lysate and 
elutes from Healthy Controls (HC), ALS-Fast and ALS-Slow DBS is about 8 to 10 fold lower than total protein 
concentration measured in matched plasma samples. There are no differences in the DBS protein levels between 
HC and ALS patients. (F) Significant correlation between Haemoglobin (Hb), Haematocrit (Hct) and total 
protein concentrations measured in DBS obtained from the same blood samples (p = 0.0019, R2 = 0.32 and 
p = 0.0055, R2 = 0.28 respectively; linear regression analysis). DF: dilution factor.
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peripheral blood mononuclear cell (PBMCs) extracted from the same HC and ALS patient’ samples. Nf-L bands 
in RBCs appeared at approximately the same MW levels as those detected in DBS elute (high intensity 52 kDa and 
14 kDa bands with a fainter 28 kDa band). This finding strongly supports the presence of Nf-L in erythrocytes. No 
Nf-L bands were detected in PBMCs.
Nf-L measurement in red blood cells by single molecular array (Simoa). Nf-L measurement was 
performed in both plasma and red blood cells samples from n.6 Fast ALS and n.7 Healthy Controls (HC) using the 
Simoa platform (Fig. 5A). Nf-L appeared expressed in RBCs and compared to the Nf-L analysis in the matched 
plasma samples, it was (non-significantly) over-expressed in RBCs from ALS patients compared to HC (Fig. 5A). 
There was a significant correlation between the NF-L levels in plasma and in RBCs (r2 = 0.74 p < 0.0001; Fig. 5B).
Discussion
In this study, we look at the measurement of Nf-L, an emerging biomarker of neurodegeneration, in microsam-
ples of blood collected and stored in dried blood spots (DBS) and in plasma obtained from dry plasma spots 
(DPS). Using the most sensitive immunoassays currently available, we show that Nf-L measurement in products 
of elution from DBS is possible, but qualitatively and quantitatively different from determinations in plasma 
obtained using standard processing of the same blood samples DBS are derived from. This may be explained 
by the interference in the antibody-based analysis of high concentration of haemoglobin and of cell membrane 
proteins retained after elution of DBS, which are in a different dilution state compared to the highly concentrated 
extra-cellular protein mix found in processed plasma samples.
Nf-L detection in DBS elute is constrained by factors which are intrinsic to the physical interaction of whole 
blood with the saver card, whose effect on the release of protein upon dilution is far from being understood. 
Despite these neurochemical differences, Nf-L levels in DBS elutes provide a good level of discrimination between 
ALS and age-matched controls when Nf-L measurement in plasma is used as reference. It is nevertheless unclear 
to what extent Nf-L analysis using DBS elutes would be possible and by all means, informative, in clinical situa-
tions where Nf-L levels are expected to be much lower than the high blood concentration normally encountered 
under ALS pathological conditions and in the same age group control individuals. For example, the detection of 
minor changes in the lower picomolar or sub-picomolar range of Nf-L concentrations found in blood from new-
born babies may not be possible, a problem that may limit considerably the use of DBS for Nf-L analysis in an area 
of medicine where difficult access to blood and the importance of subtle Nf-L changes linked to brain hypoxia, 
would see the use of DBS as an important development in routine clinical practice.
However, given the mounting evidence that Nf-L is an informative biomarker of axonal loss with a potential 
widespread use in clinical studies of neurodegeneration, ageing and post-natal brain injury, the importance of our 
preliminary and proof of principle data rests primarily on the fact that inexpensive remote collection, storage and 
transport of blood without the need of a cold-chain maintenance, could potentially be deployed in the develop-
ment of large scale and population-based investigations into the bioavailability of Nf-L22.
Figure 2. Example of 4–12% Comassie gel resolution of plasma (P), serum (S), dry blood spots (DBS) eluted 
at PH 4,5, -7,4, -8,6 and 9, dry plasma spot (DPS) and products of elution from protein saver cards spotted 
with serum (dry serum spot – DSS) obtained from the same individual’ blood sample. Plasma and serum 
were diluted 1:100 at room temperature (RT) while DBS were diluted 1:60 after 1 h at 37 °C. The same protein 
concentration was loaded in each lane for all samples (100 micrograms/lane). Gel bands from P, S and from DPS 
and DSS appear equivalent. Arrows indicate DBS bands which are different from those obtained from P, S, DPS 
and DSS, particularly at low molecular weight (red cell lysis products). The bottom large and intense bands in 
the DBS lanes are likely to be products of haemolysis. The most prominent band just above 71 kDa is albumin. 
The high concentration of albumin is likely to affect electrophoretic migration, skewing the correspondent band 
position (with respect to the protein marker, M) slightly above the expected molecular weight (66 kDa). M: 
protein marker.
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Work is ongoing to broaden our knowledge on Nf expression in bio-fluids and establish how Nf levels change 
as a consequence of injury, remodelling and plasticity in affected brain tissue, or simply as a consequence of the 
progressive brain volume loss associated with ageing which is accelerated in neurodegenerative disorders23–25. To 
reduce costs associated with traditional blood sample collection, processing and storage, efforts to devise effective 
systems for remote blood collection and RT storage have multiplied26. Drops of blood for biochemical analysis 
can be collected as capillary (whole) blood after finger pricking, a minimally invasive alternative to venepuncture 
circumventing the need for phlebotomy and attendance to busy Outpatient Departments13. DBS and DPS can be 
safely kept at RT and posted to a reference lab without any further processing and storage at ultra-low tempera-
ture, as otherwise required for conventionally processed plasma and serum samples. The importance of the wide 
Figure 3. Nf-L analysis by MSD and Simoa in plasma samples, DBS and DPS elutes. A.1, A.2: Nf-L 
measurement using MSD in plasma and DBS elutes with equal volume loading. There is a trend of Nf-L 
up-regulation in DBS elutes from ALS-Fast compared to ALS-Slow and HC which does not reach statistical 
significance, while Nf-L analysis in matched plasma samples shows the expected statistically significant 
up-regulation of Nf-L in ALS-Fast compared to ALS-Slow and HC (multiple comparisons Kruskal-Wallis 
test: HC vs ALS-Slow p = 0.002; HC vs ALS-Fast p < 0.0001). In DBS elutes from controls, three values were 
below the low limit detection (<6 pg/ml: 3.6, 4.8 and 2.4 pg/ml). A.3, Passing–Bablok regression statistical 
analysis showing a modest correlation between plasma Nf-L levels and matched DBS elute Nf-L/Haematocrit 
ratios (intercept interval includes 1 and the slope coefficient includes 0). B.1, B.2: Nf-L analysis in plasma and 
DBS elutes using equivalent loading concentration (10 µg/µl) performed using Simoa. Group analysis using 
Kruskal-Wallis test, demonstrated statistically significant upregulation of Nf-L in ALS-Fast compared to HC 
(p < 0.0001) in DBS elutes similarly to what shown for matched plasma samples (p < 0.0001). Differences 
between ALS-Fast and ALS-Slow are significant in plasma, but not in DBS. B.3: Linear regression analysis 
showing positive correlation between Nf-L levels obtained from plasma samples and from DBS elutes (Simoa; 
p < 0.0001, R2 = 0.7). C.1: Positive correlation between Nf-L levels in elutes from dry plasma spots (Noviplex 
cards, Np-DPS) and matched plasma samples using a linear regression analysis, (p < 0.0001, R2 0.9). DBS: dry 
blood spots, DPS: dry plasma spots, MSD: meso-scale discovery, Simoa: single molecular array. C.2: Receiver 
operating curve (ROC) analysis comparing plasma Nf-L and matched DBS elutes Nf-L for the separation of ALS 
individuals from controls (plasma: p < 0.0001, AUC: 0.9433; DBS elute: p < 0.0001, AUC: 1).
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implementation in clinical trials of low-cost biomarkers is paramount: biomarkers help researchers identify and 
monitor different patient sub-groups, where the disease can be defined by specific molecular, genetic or immu-
nological traits. This approach facilitates novel ‘adaptive designs’ of confirmatory trials, with inclusion of smaller 
and more homogeneous cohorts of patients and overall reduction of costs27.
For DBS to become fit for purpose in these large-scale endeavours, further investigations are clearly needed 
into the pre-analytical and analytical hurdles highlighted in this paper. This will have to include testing Nf-L 
blood levels in DBS from a variety of pathologies encompassing a range of potential Nf-L blood concentrations, 
sample preparation minimizing the confounding effect of haemoglobin and cell-membrane proteins as well as 
the use of techniques other than immunoassays that do not rely on the performance of target-specific antibodies.
DBS sampling using filter paper goes back to the early 1960s to facilitate collection of heel prick blood samples 
from newborns. While multiple examples of the potential clinical exploitation of DBS for biochemical analyses 
have emerged in the literature13,28, there has been little or no attention to the range of confounders and above all to 
the comparability that dry spots-based assays have with standard plasma/serum analyses for the same analyte. We 
believe that the need to proof-test DBS-based measurements (particularly when immunodetection is employed) 
using standard serum assays as benchmark and/or internal quality controls is paramount.
Figure 5. Nf-L analysis by Simoa in plasma and red blood cells (RBCs) from the same blood samples. (A) Nf-L 
analysis in plasma and RBCs lysates from ALS cases and HC demonstrates a statistically significant upregulation 
of Nf-L in plasma from ALS individuals compared to HC (Kruskal-Wallis test, p < 0.0022). Nf-L appears to be 
expressed in RBCs and over-expressed in ALS compared to HC. 5 (B) Positive correlation between Nf-L levels 
in matched plasma and RBCs lysates tested using Simoa (linear regression analysis, p < 0.0001, R2 = 0.74).
Figure 4. Western blot analysis of Nf-L expression in plasma, DBS elutes and RBCs obtained from the same 
blood samples. 100 µg of proteins from each blood component was loaded in a lane of a 10% gel. (A), plasma 
Nf-L expression in Healthy Controls and ALS patients showing a band at 22 kDa while a 52 kDa band is visible 
in DBS elutes. 22 kDa bands intensity demonstrate higher Nf-L expression in plasma from ALS patients 
compared to Healthy Controls. (B) WB analysis of Nf-L comparing RBCs, DBS elutes and plasma from the same 
blood samples showing similar bands in RBCs and DBS. Plasma Nf-L appears at the same 22 kDa molecular 
weight level as reported in (A). The 22 kDa band in plasma shows a higher protein abundance in ALS patients 
compared to HC. The 52 kDa band in DBS does not appear different in ALS and HC. DBS: dry blood spots. 
RBCs: red blood cells. HC: Healthy Controls.
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When whole blood dries onto the filter paper, the content of ruptured cells is released into solution only when 
DBS samples are reconstituted by elution, creating a highly diluted fluid contaminated by products of red cell lysis, 
not dissimilar to what normally recognised as haemolysed blood. As a consequence, Nf-L levels are on average 
2.8 lower in DBS elutes than in plasma samples. Using the highest sensitivity platform for plasma Nf-L analysis, 
we note that Nf-L levels in DBS elutes show a smaller range of variability (Fig. 3B.1,B.2) compared to the higher 
variability of Nf-L concentrations in matched plasma samples, despite loading the same protein amount for all 
plasma and DBS elute samples. The possible “signal attenuation” seen in the immunodetection of Nf-L using DBS 
may relate to the spurious environment of the DBS elute compared to the relative purity of proteinaceous plasma/
serum as previously reported18. The lack of correlation between plasma and matched DBS-elute samples in Nf-L 
expression (note the different scatter from the mean in plasma and DBS Nf-L values in Fig. 3B.1,B.2) suggests that 
the filter paper retention and the buffering of high concentration of haemoglobin may ultimately alter Nf-L detec-
tion. This may also explain the differences in Nf-L expression when plasma and DBS elutes are studied using WB 
(Fig. 4A) and ELISA-based methods (Fig. 3B.1,B.2). Haemolysis is a well-known confounder in the detection of a 
number of analytes, a phenomenon which may depend on the nature of the analyte and on the analytical approach 
used for their measurement29. It is important to observe that in our study, the loading of an equal protein concen-
tration and the absence of differences of haematocrit levels (Supplementary Fig. 4) did not affect the measurement 
by Simoa of Nf-L in DBS elutes and the statistical differences of group separation when DBS where compared to 
matched plasma samples. Overall, our experiments point to three potential reasons for the lower yield and differ-
ences in DBS neurofilaments measurement compared to plasma (Fig. 3A.2-B.2): (1) the reduction of the amount 
of analyte that may come off the filter paper and enter solution in a form which is suitable for analysis, (2) the 
alteration of the biochemical structure of Nf proteins (Fig. 4) which may affect the release of Nf-L fractions trans-
ferred into solution due to the process of drying and finally, (3) the interference of haemoglobin products which 
may bind to or sequester the target analyte from the pool of proteins and reduce the antibody-antigen interaction 
in a Sandwich ELISA30. The detection of a relatively high amount of Nf-L in erythrocytes when compared to other 
blood fractions (Figs. 4B and 5A) is another indication of the importance of factoring in red cell lysis when meas-
uring Nf-L in blood, considering that various degrees of haemolysis could affect plasma purity.
Nf-L measurement using DBS storage of blood micro-samples could also depend on protein fragmentation 
due to proteases activity. Proteases seem not to have a major effect on total protein recovery from DBS elute 
(Supplementary Fig. 1) but the different Nf-L protein expression profiles when plasma and DBS are compared by 
WB analysis suggest that Nf-L proteolysis is matrix-dependent (Fig. 4A). The effects of proteases on Nf derived 
from axonal injury and within extracellular fluids have been previously described31. It is possible that the proteoly-
sis of Nf depends on the fluid microenvironment and in our case, on the matrix effect of the filter which may selec-
tively retain protein fragments, thus altering the final composition of the Nf-L fragmentome and its detectability.
In this paper, we have also looked at the total protein content and at Nf-L concentration in plasma before and 
after spotting and eluting from dry filter paper (Figs. 2 and3B.3C.1), as previously done with other low-abundance 
proteins like cytokines32–34. The overall plasma protein profile which include Nf-L levels is reproduced in elutes 
from DPS, suggesting that blood micro-sampling with devices like Noviplex, which delivers plasma rather than 
a haemolysed fluid, could be the best option in the choice of a remote micro-sampling method. The high costs of 
the available DPS systems may limit their use but the likely development of more affordable DPS may soon have a 
significant impact on their use in large scale biomarkers studies involving the measurement of Nf-L.
Conclusion
Here we investigate the potential of using DBS as a biological substrate for the measurement of Nf-L in the clinical 
stratification of ALS. Nf-L analysis in DBS elute from ALS patients and aged-matched controls is possible, but 
results are qualitatively and quantitatively different from those obtained from DBS-matched plasma samples. Nf-L 
levels in DBS elute provide discrimination between controls and ALS patients and their phenotypic variants but 
normalization using known loading protein concentration is needed to adjust for the chromatographic effect of 
retained haemoglobin in the spot elute. It is unclear whether the use of DBS may provide any useful information 
in situation where, unlike ALS, Nf-L blood concentration is expected to be significantly lower. Nf-L levels in 
plasma reconstituted from Noviplex DPS (Np-DPS) cards are much closer to those obtained testing conventional 
plasma samples. DPS-based Nf-L analysis could therefore be a more reliable alternative methodology to Nf-L 
plasma analysis.
Material and Methods
Participants and biological samples. Amyotrophic lateral sclerosis (ALS) patients and healthy individ-
uals were selected from the ALS biomarkers study biorepository. Informed consent was obtained from all par-
ticipants. All research was performed in accordance with relevant regulations (Ethical approval: London and 
the City Research Ethics Committee 1 09/H0703/27). The ALS Functional Rating Scale-Revised (ALSFRS-R; 
range 1 to 48, increasing levels of neurological impairment with lower scores) was used to define the level of 
neurological involvement and the speed of disease progression. Progression rate to last visit (PRL) was calculated 
as “48 - ALSFRS-R at the last visit, divided for disease duration from onset to the last visit in months” (fast ALS 
progression: PRL > 0.9; slow ALS progression: PRL ≤ 0.6)34.
Sample collection and processing. Blood was collected by venepuncture in EDTA bottles. Drops of 
whole blood (approximately 80ul) were spotted onto dry blood spots (DBS), 5 spots for a total of 400 μl per card 
(#10534612; Whatman #903, GE Healthcare, Piscataway, NJ) and plasma was immediately recovered from the 
remaining whole blood sample by centrifugation. DBSs were dried at room temperature (cards have a flap to cover 
the sample once it is dry), then placed in zip-lock bags containing a silica desiccant. For each participants/blood 
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sample, one card was kept at RT, one stored at −80 °C and one air-dried and stored at −80 °C. Matched plasma 
samples were stored at −80 °C. Dry plasma spots (DPS) were also obtained by 1) spotting drops (80 μl) of plasma 
obtained by centrifugation onto protein saver cards (PSC) as described above or 2) spotting blood drops onto 
Noviplex Card Duo (Np-DPS), (two drops of blood on each card, https://www.shimadzu.co.uk/noviplex-cards-1), 
a newly developed micro-sampling tool used to collect volumetric samples of plasma. Noviplex plasma spots were 
kept at RT in zip-lock bags containing a silica desiccant. DBS and DPS were cut at a 6 mm radius using a Uni-Core 
round punch-tool. The puncher and cutting mats were cleaned and sterilized after each punch. PSCs kept at 
−80 °C, were taken from the freezer and kept on dry-ice until punch took place. Np-DBS discs were obtained by 
peeling off the top layer of the Noviplex Card Duo and kept at RT in their foil pouch.
Elution conditions and total protein recovery. DBS and DPS discs were placed into a 96-well ELISA 
plate containing 60 µL PBS-elution buffer per well and kept in constant shaking. Protein recovery was tested using 
the Pierce method (Pierce™ BCA Protein Assay Kit). The following conditions were tested for optimal protein 
recovery: (1) overnight incubation at 4 °C or 37 °C, one hour, (2) PH range 4.5–7.4 3) Addition to elution buffer 
of 0.05% Tween-20 and the effects of 1:50 protease inhibitor (P8340-Sigma).
Additional centrifugation steps were applied to maximize the yield of protein recovery and improve the elute 
purity from products of haemolysis: discs were removed from the 96-well plate and placed into 0.5 mL Eppendorf 
without cap and open at the bottom, which was then slotted inside a bigger 1.5 mL Eppendorf. The combined 
Eppendorfs were spun down at 10 g for 3 min and the liquid content was recovered from the bottom of the larger 
Eppendorf (10 to 20 µl) and put back into the corresponding well. Total DBS elutes from the 96 wells were placed into 
new 1.5 mL Eppendorf tubes and spun down at 20 g for 6 minutes to eliminate the erythrocyte lysate contaminant.
Noviplex DPS disc elution was performed using 100 µl of loading buffer in use for the Simoa neurofilament 
analysis (sample buffer diluent included into the Simoa Nf-L Advantage Kit-102258, Quanterix).
Red blood cell lysate was obtained using distilled water.
Protein quantification methods. Pierce and Bradford assay were used for protein quantification using a 
bovine serum albumin (BSA) internal calibrator as reported by the manifacturer (Pierce™ BCA Protein Assay Kit 
- 23227- Thermo scientific; Bio-Rad Protein Assay Kit II Bio-Rad - cat. 5000002). Gel-based separation was used 
to evaluate qualitatively and quantitatively total protein content in elutes from DBS, DPS and dry serum spots 
(DSS) and band profiles were compared across samples. DBS, DPS and DSS elutes were diluted 1:60 at different 
PHs to study the protein content by Pierce or Bradford methods.
Nf Western Blot analysis. 100 micrograms of total protein from plasma, DBS elutes and red blood cell 
lysate mixed with Laemmli buffer were loaded onto 10% acrylamide gels with a marker (SeeBlue® Plus2 Cat. 
PLC5925). After electrophoresis, proteins were transferred onto nitrocellulose membranes and blocked with 
Tris buffered saline 0.1% Tween (TBS-T) containing 5% non-fat dry milk powder and placed at −20 for 1 h at 
room temperature. Membranes were then incubated overnight with Anti-Nf-L antibody (clone EP675Y, rabbit 
monoclonal-Millipore). Enhanced chemiluminescence (ECL kit; GE Healthcare), the ChemiDoc XRS + imaging 
system and the image lab 5.2.1 (Bio-Rad) software were used for signal detection acquisition and analysis.
Nf measurement by Meso Scale Discovery (MSD) and Single Molecular Array (Simoa). ALS-Fast/
Slow (n: 19) and healthy controls (HC; n: 14) were analysed using an electrochemiluminescence (ECL) assay. 
Antibodies and assays conditions have been described in a previous publication6. Nf-L analysis by MSD was per-
formed loading 50 µl of both plasma and DBS elute. For DBS analysis we considered the ratio Nf-L/haematocrit 
(hct). Hct were was obtained in the blood samples from where DBS were sourced. Nf analysis by single molecule 
array (Simoa) was performed on the same samples tested by MSD, using a commercially available Simoa Protocol 
for Nf-L analysis (Simoa Nf-L Advantage Kit-102258, Quanterix). An equal protein concentration (10 µg/µl) was 
loaded for all samples in study. The Simoa platform was used to measure Nf-L from Np-DPS. In this case, a mix of 
n.13 HC, neurological controls and Fast/Slow ALS were used. Nf-L analysis was performed using Np-DPS elute, 
plasma and diluted plasma (7 µl of plasma were diluted with Simoa diluent buffer to a final volume of 100 µl) to 
simulate Np-DPS elute analysis conditions. The same platform was used for the measurement of Nf-L in Red blood 
cells and matched plasma. Unlike for the DBS study where equal loading protein concentration was used, for the 
measurements of Nf-L in Np-DBS, red blood cells and matched plasma, an equal loading volume was utilised.
Statistical analysis. Graph Prism v.7 was used for statistical analysis. The Passing–Bablok regression anal-
ysis was utilised to determine the correlation between DBS elute and plasma Nf-L levels measured by MSD. 
Comparison of protein expression values from DBS/Np-DPS elutes and plasma was performed using Pearson’s 
correlation analysis, while group analysis was obtained using the multiple comparisons Kruskal-Wallis test. 
Adjustment for age was also undertaken with 1) univariate general linear model with covariate of age (SPSS v25) 
and 2) calculating the expected Nf-L level in each control adding the amount of Nf-L that would be expected factor-
ing in additional 9 years of age, using the function reported by Siller et al., where a 2.2% increase of Nf-L is reported 
for each additional year of age. Together with the adjustment for age performed in the group analysis, this method 
provides an additional way to normalize for age differences between the groups based on age-related increase of 
blood Nf-L levels. Evaluation of diagnostic performance was undertaken using a Receiving Operator Characteristic 
(ROC) analysis in Graph Prism v.7, comparing plasma and DBS elutes from ALS patients and control individuals.
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